Cabaletta Bio Inc (CABA)

Dec 20, 2024

Cabaletta Bio's SWOT analysis: autoimmune CAR-T stock faces challenges, opportunities By Investing.com - Investing.com South Africa

Dec 20, 2024

Dec 20, 2024

Cabaletta Bio's SWOT analysis: autoimmune CAR-T stock faces challenges, opportunities - Investing.com

Dec 20, 2024

Dec 20, 2024

Cabaletta Bio (NASDAQ:CABA) Lowered to "Inline" Rating by Evercore ISI - MarketBeat

Dec 20, 2024

Dec 19, 2024

Wells Fargo Downgrades Cabaletta Bio (CABA) - MSN

Dec 19, 2024

Dec 19, 2024

Charles Schwab Investment Management Inc. Raises Stake in Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World

Dec 19, 2024

Dec 19, 2024

This C3.ai Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday - Benzinga

Dec 19, 2024

Dec 19, 2024

Cabaletta Bio (NASDAQ:CABA) Downgraded by Wells Fargo & Company to Equal Weight - MarketBeat

Dec 19, 2024

Dec 17, 2024

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Cuts Holdings in Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World

Dec 17, 2024

Dec 15, 2024

Cabaletta Bio's SWOT analysis: CAR-T pioneer's stock faces pivotal moment - Investing.com

Dec 15, 2024

Dec 10, 2024

Cabaletta Bio, Inc.'s (NASDAQ:CABA) latest 25% decline adds to one-year losses, institutional investors may consider drastic measures - Yahoo Finance

Dec 10, 2024

Dec 10, 2024

Is Cabaletta Bio (NASDAQ:CABA) In A Good Position To Invest In Growth? - Simply Wall St

Dec 10, 2024

Dec 10, 2024

Point72 Asset Management L.P. Makes New $3.15 Million Investment in Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat

Dec 10, 2024

Dec 06, 2024

Jennison Associates LLC Reduces Stake in Cabaletta Bio Inc - GuruFocus.com

Dec 06, 2024

Dec 06, 2024

PRUDENTIAL FINANCIAL INC's Strategic Acquisition of Cabaletta Bio Inc Shares - GuruFocus.com

Dec 06, 2024

Dec 05, 2024

Walleye Capital LLC Acquires 212,025 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat

Dec 05, 2024

Dec 03, 2024

Cabaletta Bio to Present Key Findings on CABA-201 at ACR Convergence 2024 - MSN

Dec 03, 2024

Dec 03, 2024

Weekly Analysts’ Ratings Updates for Cabaletta Bio (CABA) - Defense World

Dec 03, 2024

Dec 02, 2024

Unusually active option classes on open December 2nd - TipRanks

Dec 02, 2024

Dec 01, 2024

Cabaletta Bio (NASDAQ:CABA) Raised to Strong-Buy at TD Cowen - Defense World

Dec 01, 2024

Nov 30, 2024

Cabaletta Bio Sees Unusually High Options Volume (NASDAQ:CABA) - MarketBeat

Nov 30, 2024

Nov 29, 2024

US Stocks Likely To Open In The Green To End November On A High: Are Markets Set For A Santa Claus Rally In December? Analysts Decode - Benzinga

Nov 29, 2024

Nov 29, 2024

Cabaletta Bio, Inc. (NASDAQ:CABA) Receives $27.30 Consensus PT from Analysts - MarketBeat

Nov 29, 2024

Nov 28, 2024

Caballeta Bio Shares Surge The Most In 23 Months In A Single Day As It Unveils Plan To Meet FDA By 2025 For Systemic Sclerosis Drug Trial - Benzinga

Nov 28, 2024

Nov 27, 2024

CABA Stock Earnings: Cabaletta Bio Misses EPS for Q1 2024 - MSN

Nov 27, 2024

Nov 27, 2024

Cabaletta Bio’s CAR-T CABA-201 Effects Clinical Responses in Autoimmune Diseases - CGTLive™

Nov 27, 2024

Nov 26, 2024

Cabaletta Bio to Participate in Upcoming Investor Conferences in December - The Manila Times

Nov 26, 2024

Nov 25, 2024

2 Penny Stocks That Wall Street Predicts Will Soar 306% To 1,183% In 2025 - Barchart

Nov 25, 2024

Nov 25, 2024

2 Penny Stocks That Wall Street Predicts Will Soar 306% to 1,183% in 2025 - Inkl

Nov 25, 2024

Nov 25, 2024

Cabaletta Bio Inc (CABA-Q) QuotePress Release - The Globe and Mail

Nov 25, 2024

Nov 24, 2024

Cabaletta Bio Unveils Promising Data on CABA-201 at ACR Convergence 2024 - MSN

Nov 24, 2024

Nov 22, 2024

Cabaletta Bio, Inc. Set to Engage at Key Investor Conferences - MSN

Nov 22, 2024

Nov 20, 2024

Cabaletta Bio to Spotlight Groundbreaking Cell Therapies at Guggenheim’s Healthcare Innovation Conference! - MSN

Nov 20, 2024

Nov 20, 2024

Cabaletta Bio Reports Q3 2024 Financial Results and Clinical Trial Advancements - MSN

Nov 20, 2024

Nov 19, 2024

Cabaletta Bio shares retain Buy rating as H.C. Wainwright sees robust treatment effect - Investing.com

Nov 19, 2024

Nov 19, 2024

Cabaletta reports promising autoimmune therapy results By Investing.com - Investing.com Australia

Nov 19, 2024

Nov 18, 2024

Cabaletta Bio Reports Q3 2024 Financial Results - TipRanks

Nov 18, 2024

Nov 18, 2024

Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024 - The Manila Times

Nov 18, 2024

Nov 18, 2024

Cabaletta reports promising autoimmune therapy results - Investing.com

Nov 18, 2024

Nov 18, 2024

Cabaletta Bio’s (CABA) Buy Rating Reiterated at HC Wainwright - Defense World

Nov 18, 2024

Nov 18, 2024

Inflammatory Myositis Treatment Market: Segmentation Trends, - openPR

Nov 18, 2024

Nov 15, 2024

Cabaletta Bio (NASDAQ:CABA) Given New $12.00 Price Target at Wells Fargo & Company - MarketBeat

Nov 15, 2024

Nov 15, 2024

Cabaletta Bio stock hits 52-week low at $3.47 amid market challenges - Investing.com UK

Nov 15, 2024

Nov 15, 2024

Cabaletta Bio's (CABA) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat

Nov 15, 2024

Nov 15, 2024

Cabaletta Bio price target lowered to $12 from $20 at Wells Fargo - TipRanks

Nov 15, 2024

Nov 15, 2024

Cabaletta Bio Inc. (CABA) Quarterly 10-Q Report - Quartzy

Nov 15, 2024

Nov 14, 2024

T. Rowe Price Investment Management, Inc. Reduces Stake in Cabal - GuruFocus.com

Nov 14, 2024

Nov 14, 2024

Guggenheim maintains Buy on Cabaletta Bio with $23 target - Investing.com

Nov 14, 2024

Nov 14, 2024

Guggenheim maintains Buy on Cabaletta Bio with $23 target By Investing.com - Investing.com UK

Nov 14, 2024

Nov 14, 2024

Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times

Nov 14, 2024